

RETRACTION

DOI: 10.3892/ijo.2020.5136

Epigenetic silencing of miR-130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling

FENG GAO, FA-GANG WANG, REN-RONG LIU, FENG XUE, JIAN ZHANG, GUANG-QI XU, JIAN-HAI BI, ZHEN MENG and RAN HUO

Int J Oncol 50: 1821-1831, 2017; DOI: 10.3892/ijo.2017.3943

Following the publication of this paper, it was drawn to the authors' attention by an interested reader that some tumours featured in Fig. 6A of the above paper were strikingly similar to those featured in Fig. 8A of an article appearing in the same journal [Fan F-Y, Deng R, Yi H, Sun H-P, Zeng Y, He G-C and Su Y: The inhibitory effect of MEG3/miR-214/AIFM2 axis on the growth of T-cell lymphoblastic lymphoma. *Int J Oncol* 51: 316-326, 2017]. Furthermore, flow cytometric images featured in Fig. 2G of the above paper were strikingly similar to data featured in the following article [Zhang H-j, Wei Q-f, Wang S-j, Zhang H-j, Zhang X-y, Geng Q, Cui Y-h and Wang X-h: LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF- κ B pathway. *Int Immunopharmacol* 50: 283-290, 2017].

The Editor asked the authors for an explanation to account for the appearance of strikingly similar data in their paper independently, and they responded to request that the paper be retracted from *International Journal of Oncology*. All the authors agreed that the article should be retracted. The Editor apologizes to the readership for any inconvenience caused.



This work is licensed under a Creative Commons
Attribution 4.0 International (CC BY 4.0) License.